Skip to content
value.today

Illuminare Biotechnologies Inc

🇺🇸 Princeton, New Jersey, USABiotechnologyFounded 2016
Total raised
$6 M
2 rounds on record
Latest round
$4 M
May 2026
First round on record
Aug 2017
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Illuminare Biotechnologies Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2026$4 MNo. 2$2 to $10 million

Illuminare Biotechnologies Inc: Raise no. 2, May 2026

Investors in this round

42 investors had bought by the notice of Jun 4, 2026: 42 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered; $0 M still to sell
Smallest investment taken
$1,363
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian Longstreet · Executive Officer, Director
  • Walter Greenblatt · Executive Officer, Director, Promoter
  • Eric Edidin · Director
  • Oliver Curme · Director
  • Robert Graifman · Director, Promoter
  • Shay Grinfeld · Director, Promoter
  • Andrew Fradkin · Promoter
  • Ezra Angrist · Promoter

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On fees: “No sales commission or finders' fees.”

Signed by Ezra Angrist, Financial Consultant. Source: SEC Form D, newest notice filed Jun 4, 2026. Read the notice at the SEC.

equity, optionsSEC
Aug 2017$2 MNo. 1$2 to $10 million

Illuminare Biotechnologies Inc: Raise no. 1, Aug 2017

Investors in this round

44 investors had bought by the notice of Aug 18, 2017: 44 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $3 M offered; $0 M still to sell
Smallest investment taken
$5,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Shay Grinfeld · Executive Officer, Director
  • Robert Graifman · Director
  • Sue Yao · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Andrew Fradkin, Secretary. Source: SEC Form D, newest notice filed Aug 18, 2017. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Illuminare Biotechnologies Inc had no revenue when it filed its newest notice of a funding round (Jun 2026).

    SEC Form D (revenue range) · Jun 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2026

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Illuminare Biotechnologies Inc is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 44 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Illuminare Biotechnologies Inc
NameRoleNamed in
Brian LongstreetExecutive officerJun 2026
Walter GreenblattExecutive officerJun 2026
Shay GrinfeldExecutive officerAug 2017
Brian LongstreetDirectorJun 2026
Eric EdidinDirectorJun 2026
Oliver CurmeDirectorJun 2026
Robert GraifmanDirectorJun 2026
Shay GrinfeldDirectorJun 2026
Walter GreenblattDirectorJun 2026
Sue YaoDirectorAug 2017
Andrew FradkinPromoterJun 2026
Ezra AngristPromoterJun 2026
Robert GraifmanPromoterJun 2026
Shay GrinfeldPromoterJun 2026
Walter GreenblattPromoterJun 2026